Daniel Merrick
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 43 | 2026 | 2637 | 2.920 |
Why?
| | Precancerous Conditions | 13 | 2026 | 166 | 2.540 |
Why?
| | Carcinoma, Squamous Cell | 15 | 2024 | 641 | 1.880 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 14 | 2026 | 1180 | 1.350 |
Why?
| | Adenocarcinoma | 7 | 2019 | 928 | 0.590 |
Why?
| | B7-H1 Antigen | 3 | 2026 | 241 | 0.450 |
Why?
| | Biopsy | 9 | 2026 | 1075 | 0.450 |
Why?
| | Bronchi | 6 | 2018 | 267 | 0.430 |
Why?
| | Chemoprevention | 4 | 2019 | 90 | 0.420 |
Why?
| | Biomarkers, Tumor | 9 | 2026 | 1313 | 0.390 |
Why?
| | ErbB Receptors | 6 | 2023 | 627 | 0.380 |
Why?
| | Disease Progression | 7 | 2019 | 2847 | 0.360 |
Why?
| | Carmustine | 3 | 2020 | 52 | 0.360 |
Why?
| | Neovascularization, Pathologic | 5 | 2015 | 286 | 0.350 |
Why?
| | Heat-Shock Proteins | 1 | 2012 | 138 | 0.350 |
Why?
| | Bronchial Neoplasms | 2 | 2011 | 15 | 0.330 |
Why?
| | Papillomaviridae | 4 | 1996 | 115 | 0.320 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 612 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 623 | 0.290 |
Why?
| | Smoke | 3 | 2020 | 148 | 0.290 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2026 | 1455 | 0.290 |
Why?
| | Keratinocytes | 4 | 1996 | 248 | 0.290 |
Why?
| | Lung Diseases | 1 | 2015 | 787 | 0.290 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2024 | 339 | 0.280 |
Why?
| | Protein Kinase Inhibitors | 4 | 2026 | 969 | 0.280 |
Why?
| | Smoking | 6 | 2019 | 1472 | 0.280 |
Why?
| | Lung | 10 | 2025 | 4109 | 0.270 |
Why?
| | Gene Dosage | 3 | 2016 | 148 | 0.270 |
Why?
| | Formaldehyde | 2 | 2025 | 66 | 0.260 |
Why?
| | Carcinogenesis | 2 | 2020 | 229 | 0.260 |
Why?
| | Inflammation | 1 | 2018 | 2878 | 0.250 |
Why?
| | Epoprostenol | 2 | 2018 | 131 | 0.250 |
Why?
| | Iloprost | 4 | 2018 | 44 | 0.240 |
Why?
| | Carcinogens | 5 | 2018 | 122 | 0.240 |
Why?
| | Mice | 23 | 2026 | 18339 | 0.230 |
Why?
| | Humans | 56 | 2026 | 144759 | 0.230 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2018 | 322 | 0.220 |
Why?
| | Sputum | 4 | 2019 | 308 | 0.210 |
Why?
| | Mutation | 6 | 2023 | 4089 | 0.210 |
Why?
| | Immunohistochemistry | 5 | 2015 | 1716 | 0.200 |
Why?
| | Mast Cells | 1 | 2025 | 146 | 0.200 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 15 | 0.200 |
Why?
| | Neoplasm Invasiveness | 4 | 2015 | 508 | 0.190 |
Why?
| | Chest Pain | 1 | 2003 | 99 | 0.190 |
Why?
| | Desmoglein 3 | 2 | 2022 | 14 | 0.190 |
Why?
| | Cell Proliferation | 4 | 2018 | 2496 | 0.180 |
Why?
| | Lidocaine | 1 | 2022 | 54 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 557 | 0.180 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2022 | 219 | 0.180 |
Why?
| | Gelatin | 1 | 2022 | 56 | 0.180 |
Why?
| | Inflammation Mediators | 1 | 2025 | 509 | 0.180 |
Why?
| | Neoplasms | 3 | 2026 | 2875 | 0.180 |
Why?
| | Neuropilin-1 | 1 | 2021 | 8 | 0.180 |
Why?
| | Gene Expression Profiling | 3 | 2026 | 1782 | 0.180 |
Why?
| | Animals | 24 | 2026 | 38058 | 0.180 |
Why?
| | Male | 31 | 2026 | 72315 | 0.170 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2026 | 780 | 0.170 |
Why?
| | Ki-67 Antigen | 2 | 2015 | 117 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 85 | 0.170 |
Why?
| | Middle Aged | 20 | 2026 | 35875 | 0.170 |
Why?
| | Female | 31 | 2026 | 78271 | 0.170 |
Why?
| | Cysts | 1 | 2021 | 111 | 0.160 |
Why?
| | Receptor, IGF Type 1 | 2 | 2010 | 64 | 0.160 |
Why?
| | Aged | 14 | 2026 | 25913 | 0.160 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 46 | 0.150 |
Why?
| | Biomedical Research | 1 | 2026 | 710 | 0.150 |
Why?
| | Respiratory System | 1 | 2020 | 149 | 0.150 |
Why?
| | Carcinoma in Situ | 1 | 2019 | 44 | 0.150 |
Why?
| | Cell Cycle Proteins | 2 | 2018 | 628 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4557 | 0.150 |
Why?
| | Air Pollution | 1 | 2023 | 327 | 0.150 |
Why?
| | Pneumonia | 1 | 2025 | 631 | 0.150 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.140 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 370 | 0.140 |
Why?
| | Exons | 1 | 2020 | 358 | 0.140 |
Why?
| | Metaplasia | 1 | 2018 | 57 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2023 | 881 | 0.140 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.140 |
Why?
| | Mucin 5AC | 1 | 2018 | 70 | 0.140 |
Why?
| | Air Pollutants | 1 | 2023 | 438 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 233 | 0.140 |
Why?
| | MicroRNAs | 2 | 2016 | 701 | 0.140 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 61 | 0.140 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 99 | 0.130 |
Why?
| | Urethane | 4 | 2023 | 43 | 0.120 |
Why?
| | Aged, 80 and over | 7 | 2017 | 8265 | 0.120 |
Why?
| | Cell Transformation, Viral | 2 | 1993 | 23 | 0.120 |
Why?
| | RNA, Messenger | 5 | 2022 | 2832 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 558 | 0.120 |
Why?
| | Frizzled Receptors | 1 | 2016 | 25 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.120 |
Why?
| | Prognosis | 6 | 2026 | 4282 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 154 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 210 | 0.120 |
Why?
| | Porphyrins | 1 | 2015 | 16 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 75 | 0.120 |
Why?
| | Tomography, Spiral Computed | 1 | 2015 | 30 | 0.120 |
Why?
| | Oncogenes | 1 | 2016 | 119 | 0.110 |
Why?
| | Adult | 13 | 2026 | 40449 | 0.110 |
Why?
| | Myocardial Infarction | 1 | 2003 | 1209 | 0.110 |
Why?
| | Topoisomerase Inhibitors | 1 | 2015 | 4 | 0.110 |
Why?
| | Smad4 Protein | 1 | 2015 | 34 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 433 | 0.110 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 410 | 0.100 |
Why?
| | Chromosomal Instability | 1 | 2013 | 21 | 0.100 |
Why?
| | Macrophages, Alveolar | 2 | 2023 | 368 | 0.100 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2182 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2013 | 117 | 0.100 |
Why?
| | Stem Cells | 1 | 2018 | 626 | 0.100 |
Why?
| | Neoplasms, Basal Cell | 1 | 2013 | 4 | 0.100 |
Why?
| | Obesity | 1 | 2007 | 3077 | 0.100 |
Why?
| | Trachea | 1 | 2015 | 261 | 0.100 |
Why?
| | Endoscopy | 1 | 2015 | 316 | 0.100 |
Why?
| | Interleukin-1 | 1 | 1996 | 961 | 0.090 |
Why?
| | Tretinoin | 1 | 1993 | 124 | 0.090 |
Why?
| | Quinazolines | 2 | 2012 | 266 | 0.090 |
Why?
| | Piperidines | 2 | 2012 | 217 | 0.090 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 57 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 1992 | 77 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 876 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2013 | 164 | 0.090 |
Why?
| | Cohort Studies | 3 | 2023 | 5960 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 983 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1129 | 0.080 |
Why?
| | Cell Line | 4 | 2019 | 2882 | 0.080 |
Why?
| | Hyperplasia | 1 | 2011 | 174 | 0.080 |
Why?
| | Tissue Array Analysis | 3 | 2019 | 50 | 0.080 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2012 | 230 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1489 | 0.080 |
Why?
| | Epithelium | 4 | 2018 | 314 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 920 | 0.080 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.080 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 463 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1953 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 383 | 0.080 |
Why?
| | Nuclear Proteins | 3 | 2006 | 748 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 851 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2011 | 331 | 0.070 |
Why?
| | Cell Polarity | 1 | 2010 | 137 | 0.070 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2010 | 119 | 0.070 |
Why?
| | Epithelial Cells | 4 | 2018 | 1125 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2020 | 1462 | 0.070 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2008 | 69 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5408 | 0.070 |
Why?
| | Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.070 |
Why?
| | Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 3 | 0.070 |
Why?
| | Smokers | 2 | 2019 | 137 | 0.070 |
Why?
| | Echocardiography | 2 | 2003 | 652 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 173 | 0.070 |
Why?
| | Prevalence | 3 | 2023 | 2834 | 0.070 |
Why?
| | Edema | 1 | 2008 | 124 | 0.060 |
Why?
| | Carcinoma, Small Cell | 1 | 2008 | 173 | 0.060 |
Why?
| | Fibroblast Growth Factors | 1 | 2008 | 188 | 0.060 |
Why?
| | Monocytes | 1 | 2010 | 538 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2608 | 0.060 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 171 | 0.060 |
Why?
| | Genome-Wide Association Study | 1 | 2013 | 1406 | 0.060 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 636 | 0.060 |
Why?
| | Minichromosome Maintenance Complex Component 2 | 1 | 2006 | 4 | 0.060 |
Why?
| | Placebos | 2 | 2019 | 192 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2145 | 0.060 |
Why?
| | Hydrogels | 2 | 2023 | 700 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5992 | 0.060 |
Why?
| | United Kingdom | 1 | 2007 | 338 | 0.060 |
Why?
| | Survival Rate | 2 | 2026 | 2089 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4271 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2020 | 48 | 0.060 |
Why?
| | Cell Movement | 2 | 2025 | 965 | 0.060 |
Why?
| | Transcription Factors | 1 | 1993 | 1741 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2022 | 11679 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2021 | 732 | 0.060 |
Why?
| | Gene Rearrangement | 1 | 2026 | 155 | 0.060 |
Why?
| | Environment | 1 | 2007 | 305 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2017 | 162 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 253 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 109 | 0.050 |
Why?
| | Bronchoscopy | 2 | 2019 | 227 | 0.050 |
Why?
| | Specimen Handling | 1 | 2026 | 186 | 0.050 |
Why?
| | Hypoxia | 1 | 2012 | 1199 | 0.050 |
Why?
| | Global Health | 1 | 2007 | 401 | 0.050 |
Why?
| | Prospective Studies | 4 | 2023 | 7990 | 0.050 |
Why?
| | Japan | 1 | 2003 | 143 | 0.050 |
Why?
| | Gene Knockdown Techniques | 2 | 2015 | 336 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 70 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 48 | 0.050 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1326 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2003 | 175 | 0.040 |
Why?
| | Aniline Compounds | 1 | 2023 | 119 | 0.040 |
Why?
| | Alveolar Epithelial Cells | 1 | 2023 | 120 | 0.040 |
Why?
| | Up-Regulation | 1 | 2005 | 851 | 0.040 |
Why?
| | Signal Transduction | 3 | 2012 | 5226 | 0.040 |
Why?
| | Immunoenzyme Techniques | 2 | 2012 | 200 | 0.040 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 432 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2023 | 169 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1253 | 0.040 |
Why?
| | Particle Size | 1 | 2023 | 411 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2025 | 499 | 0.040 |
Why?
| | Interferon-gamma | 2 | 2018 | 784 | 0.040 |
Why?
| | PPAR gamma | 1 | 2022 | 176 | 0.040 |
Why?
| | Tubulin | 1 | 2022 | 147 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1985 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2023 | 395 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2019 | 2029 | 0.040 |
Why?
| | Incidence | 2 | 2008 | 2879 | 0.040 |
Why?
| | Acute Disease | 1 | 2003 | 1030 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 634 | 0.040 |
Why?
| | Oximes | 1 | 2020 | 26 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 347 | 0.040 |
Why?
| | Electrocardiography | 1 | 2003 | 662 | 0.040 |
Why?
| | Blotting, Western | 2 | 2012 | 1187 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2020 | 126 | 0.040 |
Why?
| | Pyrimidines | 1 | 2023 | 532 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2020 | 304 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 209 | 0.040 |
Why?
| | Cell Line, Transformed | 2 | 1996 | 140 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 389 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 501 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 254 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 307 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 338 | 0.030 |
Why?
| | Tobacco Smoking | 1 | 2018 | 26 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2023 | 588 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 66 | 0.030 |
Why?
| | Pyridones | 1 | 2020 | 199 | 0.030 |
Why?
| | RNA | 1 | 2005 | 940 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2452 | 0.030 |
Why?
| | Tricuspid Valve | 1 | 1998 | 41 | 0.030 |
Why?
| | Time | 1 | 2018 | 86 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 635 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 225 | 0.030 |
Why?
| | Ventricular Outflow Obstruction | 1 | 1998 | 40 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 162 | 0.030 |
Why?
| | Risk Factors | 3 | 2019 | 10779 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2017 | 164 | 0.030 |
Why?
| | Tumor Burden | 1 | 2018 | 319 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 183 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 160 | 0.030 |
Why?
| | Mass Screening | 2 | 2004 | 1347 | 0.030 |
Why?
| | Carcinogenicity Tests | 1 | 1996 | 10 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2006 | 1098 | 0.030 |
Why?
| | Immunotherapy | 1 | 2021 | 653 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 570 | 0.030 |
Why?
| | Blotting, Northern | 1 | 1996 | 204 | 0.030 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 1996 | 49 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2016 | 4154 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 1996 | 251 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 71 | 0.030 |
Why?
| | Plasmids | 1 | 1996 | 379 | 0.030 |
Why?
| | Mitotic Index | 1 | 2015 | 25 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 439 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1382 | 0.030 |
Why?
| | Mice, Nude | 1 | 1996 | 682 | 0.030 |
Why?
| | Cell Differentiation | 2 | 1993 | 2050 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 549 | 0.030 |
Why?
| | Phenotype | 2 | 1993 | 3162 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2013 | 52 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1993 | 38 | 0.030 |
Why?
| | Receptors, Retinoic Acid | 1 | 1993 | 42 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2017 | 1126 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1996 | 267 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 1993 | 154 | 0.020 |
Why?
| | Computational Biology | 1 | 2018 | 680 | 0.020 |
Why?
| | Drug Resistance | 1 | 1993 | 153 | 0.020 |
Why?
| | Cytosol | 1 | 1993 | 227 | 0.020 |
Why?
| | Models, Molecular | 1 | 2018 | 1618 | 0.020 |
Why?
| | Macrophages | 1 | 2020 | 1511 | 0.020 |
Why?
| | DNA Repair | 1 | 2015 | 256 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 2012 | 21 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2012 | 38 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 36 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2012 | 3540 | 0.020 |
Why?
| | Respiratory Mucosa | 1 | 2015 | 322 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1992 | 49 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 1992 | 57 | 0.020 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 1993 | 209 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 389 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 150 | 0.020 |
Why?
| | Keratins | 1 | 1992 | 172 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 340 | 0.020 |
Why?
| | Sleep Apnea Syndromes | 1 | 2012 | 97 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 167 | 0.020 |
Why?
| | United States | 2 | 2011 | 15966 | 0.020 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 17 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 2194 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 847 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.020 |
Why?
| | Cell Division | 1 | 1992 | 766 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2925 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 397 | 0.020 |
Why?
| | Aneuploidy | 1 | 2010 | 90 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 206 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 928 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 549 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 769 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 965 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1325 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5868 | 0.010 |
Why?
| | Asia | 1 | 2006 | 70 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2027 | 0.010 |
Why?
| | Skin | 1 | 1991 | 755 | 0.010 |
Why?
| | Databases, Nucleic Acid | 1 | 2005 | 39 | 0.010 |
Why?
| | England | 1 | 2006 | 111 | 0.010 |
Why?
| | Enzymes | 1 | 2005 | 65 | 0.010 |
Why?
| | Age Distribution | 1 | 2006 | 403 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3604 | 0.010 |
Why?
| | Sex Distribution | 1 | 2006 | 386 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 574 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 2061 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2005 | 521 | 0.010 |
Why?
| | DNA Replication | 1 | 2005 | 251 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2430 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 758 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3333 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1519 | 0.010 |
Why?
| | Body Weight | 1 | 2006 | 976 | 0.010 |
Why?
| | Models, Statistical | 1 | 2006 | 681 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 14105 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3671 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7173 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 17066 | 0.010 |
Why?
| | Echocardiography, Transesophageal | 1 | 1998 | 133 | 0.010 |
Why?
| | Infant | 1 | 2006 | 10034 | 0.010 |
Why?
| | Culture Techniques | 1 | 1991 | 67 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2583 | 0.010 |
Why?
| | Child, Preschool | 1 | 2006 | 11787 | 0.010 |
Why?
| | Reference Values | 1 | 1991 | 797 | 0.000 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3890 | 0.000 |
Why?
| | Adolescent | 1 | 2006 | 22428 | 0.000 |
Why?
| | Child | 1 | 2006 | 22633 | 0.000 |
Why?
|
|
Merrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|